Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Fig. 4

Responses by baseline BCR-ABL1 mutation status in the chronic phase (A) or accelerated phase (B) using Sanger sequencing. CCyR, complete cytogenetic response; MCyR, major cytogenetic response; MMR, major molecular response; MR4.0, molecular response 4; MR4.5, molecular response 4.5

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us